RecruitingNCT07036991

A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis

A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis (TRIP-CAS)


Sponsor

Changhai Hospital

Enrollment

406 participants

Start Date

Sep 5, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

A multicenter cohort study


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Evolocumab (biweekly injections) + Rosuvastatin/Atorvastatin ± Ezetimibe and a drug called Rosuvastatin/Atorvastatin ± Ezetimibe for people with carotid artery stenosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEvolocumab (biweekly injections) + Rosuvastatin/Atorvastatin ± Ezetimibe

PCSK9 inhibitor (biweekly injections) + rosuvastatin/atorvastatin ± ezetimibe

DRUGRosuvastatin/Atorvastatin ± Ezetimibe

Rosuvastatin/atorvastatin ± ezetimibe


Locations(1)

Changhai Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07036991


Related Trials